TECXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Tectonic Therapeutic, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$21.15+0.50 (+2.42%)
Close on Oct 19, 2026
- Market cap
- $401.09M
- P/E (TTM)
- –
- Dividend yield
- 0.00%
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
71.4%
14M of 20M shares
Institutional holders
123
25 new, 11 sold out
Net institutional buying
0M
In Q2 2026
Insider trades, 12 months
3 buys · 10 sales
Net sold $403.50K
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Terrance McGuire | 657,976 | 6.30% | 13D (active) amendment | Apr 3, 2025 |
| Timothy A. Springer | 4,313,558 | 31.50% | 13D (active) amendment | Apr 3, 2025 |
| ADAR1 Capital Management GP, LLC | 3,276,498 | 7.40% | 13G (passive) | Feb 15, 2024 |
| FMR LLC | 2,799,400 | 15.00% | 13G (passive) amendment | Mar 31, 2025 |
| Abigail P. Johnson | 1,516,335 | 10.30% | 13G (passive) amendment | Dec 31, 2024 |
| Deep Track Capital, LP | 1,401,938 | 7.60% | 13G (passive) | Feb 3, 2025 |
| Chen Yu | 1,169,760 | 6.20% | 13G (passive) | Feb 12, 2026 |
| abrdn Inc | 1,141,824 | 6.10% | 13G (passive) | Dec 31, 2025 |
| VV Manager II, LLC | 1,028,674 | 5.60% | 13D (active) amendment | Feb 5, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of TECX | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| FMR LLC | 2,830,378 | 14.48% | $97.29M | +13,884 | 0.00% |
| TCG Crossover Management, LLC | 1,204,891 | 6.16% | $41.42M | – | 1.00% |
| abrdn plc | 1,141,824 | 5.84% | $39.25M | – | 0.06% |
| BlackRock, Inc. | 862,592 | 4.41% | $29.65M | +2,240 | 0.00% |
| First Light Asset Management, LLC | 800,726 | 4.10% | $27.52M | +152,983 | 1.67% |
| Baker Bros. Advisors LP | 607,788 | 3.11% | $20.89M | – | 0.10% |
| 5AM Venture Management, LLC | 606,660 | 3.10% | $20.85M | – | 7.24% |
| Braidwell LP | 596,900 | 3.05% | $20.52M | −250,251 | 0.76% |
| Vanguard Capital Management LLC | 488,805 | 2.50% | $16.80M | +15,273 | 0.00% |
| Vestal Point Capital, LP | 425,000 | 2.17% | $14.61M | +97,000 | 0.34% |
| Bollard Group LLC | 302,953 | 1.55% | $10.41K | – | 0.32% |
| Kennedy Capital Management LLC | 282,202 | 1.44% | $9.70M | −4,480 | 0.17% |
| Geode Capital Management, LLC | 270,461 | 1.38% | $9.30M | +2,188 | 0.00% |
| Orbimed Advisors LLC | 226,600 | 1.16% | $7.79M | – | 0.14% |
| State Street Corp | 219,908 | 1.12% | $7.56M | +6,403 | 0.00% |
| Ikarian Capital, LLC | 205,837 | 1.05% | $7.08M | +48,300 | 0.76% |
| D. E. Shaw & Co., Inc. | 186,550 | 0.95% | $6.41M | +70,430 | 0.00% |
| Marshall Wace, Llp | 172,101 | 0.88% | $5.92M | −57,494 | 0.00% |
| Millennium Management LLC | 165,525 | 0.85% | $5.69M | +107,177 | 0.00% |
| Squarepoint Ops LLC | 145,028 | 0.74% | $4.99M | −19,391 | 0.01% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 123 | 14M | 71.4% | 25 / 39 | 40 / 11 | 1M | 1M |
| Q1 2026 | 111 | 14M | 70.6% | 29 / 33 | 37 / 20 | 4M | 3M |
| Q4 2025 | 105 | 14M | 70.7% | 30 / 35 | 24 / 23 | 4M | 3M |
| Q3 2025 | 99 | 12M | 62.0% | 28 / 30 | 20 / 11 | 3M | 3M |
| Q2 2025 | 82 | 12M | 62.0% | 18 / 34 | 13 / 14 | 2M | 1M |
| Q1 2025 | 78 | 11M | 57.4% | 30 / 29 | 12 / 22 | 6M | 2M |
| Q4 2024 | 70 | 8M | 39.3% | 25 / 21 | 15 / 8 | 2M | 1M |
| Q3 2024 | 53 | 7M | 36.9% | 19 / 12 | 9 / 4 | 3M | 1M |
| Q2 2024 | 39 | 5M | 27.3% | 39 / 0 | 0 / 0 | 5M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of TECX | Value | % of fund | As of |
|---|---|---|---|---|---|
| Fidelity Growth Company Fund | 720,235 | 3.68% | $22.45M | 0.02% | May 31, 2026 |
| Select Biotechnology Portfolio | 405,389 | 2.07% | $12.63M | 0.24% | May 31, 2026 |
| Vanguard Total Stock Market Index Fund | 364,413 | 1.86% | $12.53M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 268,951 | 1.38% | $9.25M | 0.01% | Jun 30, 2026 |
| Fidelity Growth Company K6 Fund | 248,743 | 1.27% | $7.75M | 0.03% | May 31, 2026 |
| Fidelity Series Growth Company Fund | 196,522 | 1.01% | $6.12M | 0.03% | May 31, 2026 |
| Columbia Small Cap Growth Fund | 121,484 | 0.62% | $3.79M | 0.10% | May 31, 2026 |
| Fidelity Advisor Biotechnology Fund | 120,995 | 0.62% | $3.39M | 0.15% | Jul 31, 2026 |
| Fidelity Small Cap Index Fund | 112,159 | 0.57% | $3.14M | 0.01% | Jul 31, 2026 |
| Vanguard Extended Market Index Fund | 111,919 | 0.57% | $3.85M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 Value ETF | 78,065 | 0.40% | $2.68M | 0.02% | Jun 30, 2026 |
| iShares Biotechnology ETF | 66,553 | 0.34% | $2.29M | 0.03% | Jun 30, 2026 |
| Vanguard Russell 2000 Index Fund | 56,310 | 0.29% | $1.75M | 0.01% | May 31, 2026 |
| Fidelity Extended Market Index Fund | 50,753 | 0.26% | $1.58M | 0.00% | May 31, 2026 |
| iShares Micro-Cap ETF | 34,417 | 0.18% | $1.18M | 0.08% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Alise Reicin | Chief Executive Officer, Director | 437,653 | 2.24% | Sep 8, 2026 |
| Daniel Lochner | Chief Financial Officer | 58,544 | 0.30% | Sep 8, 2026 |
| Peter McNamara | Chief Scientific Officer | 55,328 | 0.28% | Sep 8, 2026 |
| Marc Schwabish | Chief Business Officer | 45,314 | 0.23% | Sep 8, 2026 |
| Marcella K. Ruddy | Chief Medical Officer | 67,682 | 0.35% | Sep 8, 2026 |
| Jessica Caroline Chutter | Director | – | – | Jun 10, 2026 |
| Phillip B. Donenberg | Director | 2,000 | 0.01% | Jun 10, 2026 |
| Timothy A. Springer | Director, 10% owner | 6,024,338 | 30.82% | Jun 10, 2026 |
| Stefan Vitorovic | Director | 1,000,900 | 5.12% | Jun 10, 2026 |
| Praveen P. Tipirneni | Director | 3,037 | 0.02% | Jun 10, 2026 |
| Francois Nader | Director | – | – | Apr 3, 2026 |
| Terrance McGuire | Director | 573,062 | 2.93% | Jun 11, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Peter McNamara Chief Scientific Officer | Aug 25, 2026 | Option exercise | +43 | $14.71 | $633 | 55,328 |
| Peter McNamara Chief Scientific Officer | Aug 25, 2026 | Sale(10b5-1 plan) | −43 | $36.52 | $1.57K | 55,285 |
| Peter McNamara Chief Scientific Officer | Aug 12, 2026 | Sale(10b5-1 plan) | −43 | $35.00 | $1.51K | 55,285 |
| Peter McNamara Chief Scientific Officer | Aug 12, 2026 | Option exercise | +43 | $14.71 | $633 | 55,328 |
| Peter McNamara Chief Scientific Officer | Jun 30, 2026 | Sale(10b5-1 plan) | −172 | $35.00 | $6.02K | 55,285 |
| Peter McNamara Chief Scientific Officer | Jun 30, 2026 | Option exercise | +172 | $14.71 | $2.53K | 55,457 |
| Alise Reicin Chief Executive Officer, Director | Jun 20, 2026 | Tax withholding | −924 | $30.34 | $28.03K | 310,623 |
| Marcella K. Ruddy Chief Medical Officer | May 4, 2026 | Sale(10b5-1 plan) | −1,065 | $30.00 | $31.95K | 67,682 |
| Marcella K. Ruddy Chief Medical Officer | Apr 1, 2026 | Sale(10b5-1 plan) | −1,000 | $31.05 | $31.05K | 68,747 |
| Marcella K. Ruddy Chief Medical Officer | Mar 6, 2026 | Sale(10b5-1 plan) | −10,000 | $30.00 | $300.00K | 69,747 |
| Peter McNamara Chief Scientific Officer | Mar 6, 2026 | Option exercise | +2,500 | $2.38 | $5.95K | 61,332 |
| Peter McNamara Chief Scientific Officer | Mar 6, 2026 | Sale(10b5-1 plan) | −6,047 | $30.00 | $181.41K | 55,500 |
| Peter McNamara Chief Scientific Officer | Mar 6, 2026 | Option exercise | +215 | $14.71 | $3.16K | 61,547 |
| Peter McNamara Chief Scientific Officer | Mar 6, 2026 | Sale(10b5-1 plan) | −215 | $35.00 | $7.53K | 55,285 |
| Alise Reicin Chief Executive Officer, Director | Mar 4, 2026 | Award | +76,500 | – | – | 311,547 |
| Marc Schwabish Chief Business Officer | Mar 4, 2026 | Award | +19,500 | – | – | 45,314 |
| Daniel Lochner Chief Financial Officer | Mar 4, 2026 | Award | +26,500 | – | – | 58,544 |
| Peter McNamara Chief Scientific Officer | Mar 4, 2026 | Award | +23,000 | – | – | 60,482 |
| Peter McNamara Chief Scientific Officer | Mar 4, 2026 | Sale(10b5-1 plan) | −1,650 | $25.00 | $41.25K | 58,832 |
| Marcella K. Ruddy Chief Medical Officer | Mar 4, 2026 | Award | +26,500 | – | – | 79,747 |
| Peter McNamara Chief Scientific Officer | Mar 3, 2026 | Sale(10b5-1 plan) | −1,649 | $22.06 | $36.38K | 37,482 |
| Alise Reicin Chief Executive Officer, Director | Feb 11, 2026 | Buy | +2,500 | $21.10 | $52.75K | 127,030 |
| Alise Reicin Chief Executive Officer, Director | Feb 11, 2026 | Buy | +2,500 | $21.10 | $52.75K | 237,547 |
| Marc Schwabish Chief Business Officer | Feb 10, 2026 | Option exercise | +4,500 | $2.38 | $10.71K | 25,814 |
| Daniel Lochner Chief Financial Officer | Feb 10, 2026 | Buy | +6,000 | $21.61 | $129.66K | 32,044 |
| Peter McNamara Chief Scientific Officer | Feb 4, 2026 | Tax withholding | −1,748 | $23.22 | $40.59K | 39,131 |
| Marc Schwabish Chief Business Officer | Feb 4, 2026 | Tax withholding | −1,619 | $23.22 | $37.59K | 21,314 |
| Daniel Lochner Chief Financial Officer | Feb 4, 2026 | Tax withholding | −2,077 | $23.22 | $48.23K | 26,044 |
| Marcella K. Ruddy Chief Medical Officer | Feb 4, 2026 | Tax withholding | −2,064 | $23.22 | $47.93K | 53,247 |
| Alise Reicin Chief Executive Officer, Director | Feb 4, 2026 | Tax withholding | −4,104 | $23.22 | $95.29K | 235,047 |
| Alise Reicin Chief Executive Officer, Director | Dec 31, 2025 | Option exercise | +10,966 | $2.38 | $26.10K | 239,151 |
| Peter McNamara Chief Scientific Officer | Dec 22, 2025 | Option exercise | +7,000 | $2.98 | $20.86K | 40,879 |
| Peter McNamara Chief Scientific Officer | Sep 25, 2025 | Award | +4,550 | – | – | 33,879 |
| Marc Schwabish Chief Business Officer | Sep 25, 2025 | Award | +4,210 | – | – | 22,933 |
| Daniel Lochner Chief Financial Officer | Sep 25, 2025 | Award | +5,430 | – | – | 28,121 |
| Marcella K. Ruddy Chief Medical Officer | Sep 25, 2025 | Award | +5,370 | – | – | 55,311 |
| Alise Reicin Chief Executive Officer, Director | Sep 25, 2025 | Award | +14,700 | – | – | 228,185 |
| Alise Reicin Chief Executive Officer, Director | Jun 20, 2025 | Tax withholding | −859 | $19.81 | $17.02K | 213,485 |
| Timothy A. Springer Director, 10% owner | Apr 11, 2025 | Buy | +9,478 | $16.31 | $154.59K | 4,334,846 |
| Timothy A. Springer Director, 10% owner | Apr 11, 2025 | Buy | +53,706 | $16.31 | $875.94K | 1,503,358 |
| Timothy A. Springer Director, 10% owner | Apr 10, 2025 | Buy | +45,858 | $16.73 | $767.20K | 1,449,652 |
| Timothy A. Springer Director, 10% owner | Apr 10, 2025 | Buy | +8,092 | $16.73 | $135.38K | 4,325,368 |
| Timothy A. Springer Director, 10% owner | Apr 9, 2025 | Buy | +16,215 | $14.62 | $237.06K | 1,398,938 |
| Timothy A. Springer Director, 10% owner | Apr 9, 2025 | Buy | +4,856 | $15.23 | $73.96K | 1,403,794 |
| Timothy A. Springer Director, 10% owner | Apr 9, 2025 | Buy | +857 | $15.23 | $13.05K | 4,317,276 |
| Timothy A. Springer Director, 10% owner | Apr 9, 2025 | Buy | +2,861 | $14.62 | $41.83K | 4,316,419 |
| Timothy A. Springer Director, 10% owner | Apr 7, 2025 | Buy | +87,500 | $17.10 | $1.50M | 4,313,558 |
| Timothy A. Springer Director, 10% owner | Apr 7, 2025 | Buy | +412,500 | $17.10 | $7.05M | 1,382,723 |
| Terrance McGuire Director | Apr 7, 2025 | Sale | −500,000 | $17.10 | $8.55M | 573,062 |
| Timothy A. Springer Director, 10% owner | Feb 5, 2025 | Buy | +660,000 | $50.00 | $33.00M | 970,223 |
| Timothy A. Springer Director, 10% owner | Feb 5, 2025 | Buy | +129,294 | $54.14 | $7.00M | 4,226,058 |
| Daniel Lochner Chief Financial Officer | Feb 5, 2025 | Buy | +4,617 | $54.14 | $249.96K | 4,617 |
| Daniel Lochner Chief Financial Officer | Feb 4, 2025 | Award | +18,074 | – | – | 18,074 |
| Marcella K. Ruddy Chief Medical Officer | Feb 4, 2025 | Award | +17,876 | – | – | 49,941 |
| Marc Schwabish Chief Business Officer | Feb 4, 2025 | Award | +14,023 | – | – | 18,723 |
| Peter McNamara Chief Scientific Officer | Feb 4, 2025 | Award | +15,141 | – | – | 29,329 |
| Alise Reicin Chief Executive Officer, Director | Feb 4, 2025 | Award | +36,047 | – | – | 214,344 |
| Marc Schwabish Chief Business Officer | Jan 28, 2025 | Option exercise | +2,700 | $2.38 | $6.43K | 4,700 |
| Marc Schwabish Chief Business Officer | Dec 9, 2024 | Option exercise | +2,000 | $2.38 | $4.76K | 2,000 |
| Alise Reicin Chief Executive Officer, Director | Dec 4, 2024 | Award | +11,717 | – | – | 178,297 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| McNamara Peter Officer | Sep 30, 2026 | 493 | $11.51K | Sep 30, 2026 | Restricted Stock Units |
| McGuire Terrance Former Director | Aug 27, 2026 | 7,513 | $276.72K | Aug 27, 2026 | Stock Option Exercise |
| McGuire Terrance Former Director | Aug 21, 2026 | 10,200 | $383.67K | Aug 21, 2026 | Stock Option Exercise |
| McNamara Peter Officer | Aug 12, 2026 | 129 | $4.11K | Aug 12, 2026 | Exercise of Stock Options |
| McNamara Peter Officer | Jun 30, 2026 | 172 | $5.69K | Jun 30, 2026 | Exercise of Stock Options |
| Ruddy Marcella Officer | Mar 6, 2026 | 12,065 | $336.01K | Mar 6, 2026 | Restricted Stock Units |
| McNamara Peter Officer | Mar 6, 2026 | 6,262 | $174.40K | Mar 6, 2026 | Exercise of Stock Options |
| McNamara Peter Officer | Mar 4, 2026 | 1,650 | $40.25K | Mar 4, 2026 | Restricted Stock Units |
| McNamara Peter Officer | Mar 3, 2026 | 1,649 | $37.93K | Mar 3, 2026 | Restricted Stock Units |
| Deanna M. Petersen Officer | Jul 14, 2023 | 128,648 | $177.53K | Jul 14, 2023 | STOCK OPTION EXERCISE |
| MacKay Geoff Former CEO | Jun 7, 2023 | 146,927 | $173.37K | Jun 7, 2023 | Option Exercise |
| MacKay Geoff Former CEO | Jun 5, 2023 | 7,152 | $7.94K | Jun 5, 2023 | Option Exercise |
| MacKay Geoff Former CEO | May 25, 2023 | 186,841 | $227.95K | May 25, 2023 | Private Transaction/Founders Shares |
| Mac C. MacKay Irrevocable Trust The Child of former CEO | May 24, 2023 | 72,604 | $57.34M | May 24, 2023 | Private Transaction/Founders Shares |
| Kali M. MacKay Irrevocable Trust DTD 1/6/2022 The Child of Former CEO | May 24, 2023 | 72,604 | $57.34M | May 24, 2023 | Private Transaction/Founders Shares |